In the United States, bladder cancer (BCa) is the fourth leading cancer in men and the eleventh in women. 1 In men, the incidence of BCa is approximately threefold higher than in women, which suggests that sex hormone signals may contribute to bladder tumorigenesis; however, detailed mechanisms remain unclear.
Expression of androgen receptor (AR) has been well studied and has been detected in both benign urothelium 2e4 and BCa 2e10 via immunohistochemistry (IHC). However, the reported range of AR expression in human benign urothelium and BCa varies considerably among reports, from 0% to 86% and from 0% to 78%, respectively. 2e5,7e10 The huge variation in AR expression among reports may be due to different methods of tissue preparation (eg, tissue processing and embedding in paraffin) and staining (eg, antibody, staining protocol, and criteria for positivity). 11 Most reports have suggested a higher level of AR expression in BCa than in benign urothelium; however, some reports have reached the opposite conclusion. Therefore, the correlation between AR expression and BCa remains controversial.
Two animal models that target androgen-AR signals in BCa, ie, castrated and AR knockout (ARKO) mouse models, have provided evidence for the roles of androgen-AR signaling in cancer development with distinct mechanistic explanations. Using ARKO mice, Miyamoto et al 12 reported
that the loss of AR in the entire body led to a reduced incidence of BBN-induced BCa, which suggests that AR might promote bladder tumorigenesis. Others 13, 14 have found that surgical castration and high-dose antiandrogen (flutamide) therapy reduced bladder tumorigenesis in rats. Imaoka et al 14 have suggested that castration-induced down-regulation of P450 CYP4B1, a key P450 enzyme that converts BBN [N-butyl-N-(4-hydroxybutyl)-nitrosamine] to the carcinogen BCPN [N-butyl-N-(3-carboxy-propyl)-nitrosamine], is the primary mechanism. Therefore, it remains unclear whether urothelial AR (Uro-AR) has any role in promoting bladder tumorigenesis.
To answer this question and explore the possibility of targeting Uro-AR as a therapeutic approach to BCa, we generated conditional Uro-ARKO mice (Uro-AR À/y ) that lacked AR only in urothelium. We found that Uro-AR could promote bladder tumorigenesis via modulation of p53-PCNA signals. The AR degradation enhancer ASC-J9, which degrades Uro-AR, can suppress bladder tumorigenesis.
Materials and Methods

Chemicals and Cell Line
Dihydrotestosterone and the carcinogen 3-methylcholanthrene (MCA) were purchased from Sigma-Aldrich (St. Louis, MO), and the p53 inhibitor pifithrin-a (PFT) from Enzo Life Sciences, Inc. (Farmingdale, NY). ASC-J9 was obtained from AndroScience Corp. (San Diego, CA). A human normal urothelial cell line, SV-HUC-1, was purchased from ATCC (Manassas, VA) and maintained in F-12K medium (Kaighn's modification of Ham's F-12 medium) with 10% fetal bovine serum. A human kidney epithelial cell line, 293T, was purchased from ATCC and maintained in Dulbecco's modified Eagle's medium (GIBCO Corp., Grand Island, NY) with 10% fetal bovine serum.
Plasmids and Stable Cell Lines
To generate an AR overexpressive stable clone of the SV-HUC-1 cell line, the lentivirus vectors pWPI-AR or pWPIcontrol were co-transfected with pMD2.G and pAX2 into 293T cells. After 48 hours of transfection, the cultured medium of 293T cells was harvested and mixed with fresh F-12K culture medium (ratio, 1:1) and 8 mg/mL polybrene (Millipore Corp., Billerica, MA), then incubated with SV-HUC-1 cells for 24 hours. The viral-infected SV-HUC-1 cells contained green fluorescent protein, and the SV-HUC-AR or SV-HUC-vector stable cells were obtained via flow cytometry sorting.
Generation of Urothelial ARKO Mice and Induction of BCa by BBN
All animal procedures were approved by the University Committee on Animal Resources of the University of Rochester and in accord with NIH guidelines. Male Uro-ARKO (Uro-AR À/y ) mice were generated by mating uroplakin II promoteredriven Cre (UPII-Cre) male mice 15 with flox-AR female mice. 16 After genotyping, offspring male mice were subjected to BBN-induced BCa experiments. The protocol for BBN-induced BCa was used, as in a previous study. 12 
Uro-AR
À/y and Uro-AR þ/y mice were given, ad libitum, drinking water containing 0.05% BBN (TCI America, Inc., Portland, OR), which was prepared twice a week, and BBN consumption was recorded. At age 6 weeks, mice were given drinking water containing BBN for 12 weeks, and thereafter were given water without BBN. Mice were sacrificed at age 20 or 30 weeks, and bladders were harvested and preserved in paraffin for later histologic diagnosis and IHC.
Generation of Uro-ARKO Mice with Uroplakin PromotereDriven SV40T Transgene
To generate Uro-ARKO mice with spontaneous BCa, we first mated UPII-Cre mice with UPII-SV40T mice, 17 which harbor SV40T in the urothelium, to induce BCa. After genotyping, the male offspring with both UPII-Cre and UPII-SV40T transgenes were chosen to mate with flox-AR female mice for generation of Uro-ARKO male mice with UPII-SV40T (Uro-SV40T-AR À/y ). Mice were sacrificed at 15, 20, and 30 weeks of age. Urinary tract specimens were harvested for later analysis, similarly as in the BBN-induced BCa mouse model.
Neoplastic Transformation of SV-HUC-1 Cells
The protocol for neoplastic transformation of SV-HUC-1 was used, as described in a previous study. 18 In brief, 1 Â 10 6 SV-HUC-1 cells were seeded in 100-mm culture dishes. After seeding for 48 hours, the culture medium was replaced with serum-free F12-K containing 1 nmol/L dihydrotestosterone and 5 mg/mL carcinogen MCA, with or without the p53 inhibitor PFT, at 30 mmol/L, and incubated for 48 hours. After the first 24 hours of MCA exposure, 1% fetal bovine serum was added to the medium. After 48 hours of MCA exposure, the medium was replaced with 1% fetal bovine serumeF12-K, and cells were cultured until confluent and then subcultured with 1:3 split ratio. After two additional MCA exposures as above, the SV-HUC-1 cells were cultured for 6 weeks to complete neoplastic transformation.
Western Blot Analysis
Western blot analysis was performed as previously described. 19 In brief, 50 mg protein from each cell sample was resolved via electrophoresis in 10% or 15% SDS-PAGE gels and transferred to polyvinylidene difluoride membrane (Millipore Corp.). Specific proteins were detected using antibodies against human AR (C-19; Santa Cruz Biotechnology, Inc., Santa Cruz, CA), g-H2AX (Ser139; Upstate Biotechnology, Inc., Lake Placid, NY), and b-actin (N-21; Santa Cruz Biotechnology).
Histology and IHC
Bladders were fixed in 10% buffered formalin (Sigma). After standard tissue processing, bladder tissues were embedded in paraffin. Tissue sections were treated with H&E for general histologic evaluation. All histologic data were diagnosed by our licensed pathologist (H.M.). We used the ABC kit and DAB kit (both from Vector Laboratories, Inc., Burlingame, CA) to detect AR, g-H2AX, p53, PCNA, and p21 using antibodies (from Santa Cruz Biotechnology) specific for mouse AR (C-19), g-H2AX (Ser139), p53 (FL-393), PCNA (FL-261), and p21 (F-5). The terminal deoxynucleotidyl transferaseemediated TUNEL staining assay was performed using a FluoresceinFragEL DNA Fragmentation Detection Kit (Calbiochem Corp., La Jolla, CA). Cell proliferation and apoptotic index were determined using the percentage of PCNA-and TUNELpositive cells in 100 cells from each specimen.
Suppression of Bladder Tumorigenesis in Mice via AR Degradation Enhancer ASC-J9
The AR degradation enhancer ASC-J9 was used to examine the suppression of bladder tumorigenesis induced by BBN. Six-week-old FVB male mice were subjected to BBN challenge for 12 weeks to induce BCa. When mice were aged 16 weeks, they were divided into two groups, vehicle control and ASC-J9, and subjected to daily treatment via i.p. injection (75 mg/kg body weight). At age 24 weeks, mice were sacrificed, and bladders were harvested for histologic diagnosis.
Statistical Analysis
Differences in mean values between the two groups were analyzed using the two-tailed Student's t-test. Differences in tumor incidence between the two groups were analyzed using Fisher's exact test. Difference in survival rate with BCa between the two groups was analyzed using the logrank (Mantel-Cox) test. P < 0.05 was considered statistically significant.
Results
Generation and Characterization of Mice Lacking Uro-AR
To study the role of Uro-AR in bladder tumorigenesis, we generated a new mouse model (Uro-AR À/y ) in which AR is deleted only in urothelial cells by mating male UPII-Cre mice with female flox-AR mice. The detailed mating strategy is described in Supplemental Figure S1A . The tail genotyping results demonstrated that the new Uro-AR À/y mice carried all transgenes, such as UPII-Cre and flox-AR allele (Supplemental Figure S1B) . IHC staining of the bladder from wild-type (WT; Uro-AR þ/y ) and Uro-AR À/y mice using antibody against AR C-terminal showed that partial deletion of AR was restricted to the urothelial cells and was not found in the adjacent stromal cells (Supplemental Figure S1C) . Furthermore, the serum testosterone levels were similar between 20-week-old Uro-AR À/y mice and their WT littermates (P Z 0.479) (Supplemental Figure S1D ), indicating that altered phenotypes, including bladder tumorigenesis and animal mortality, found in the Uro-AR À/y mice were not due to the mice. After 12 weeks of BBN treatment, Uro-AR þ/y and Uro-AR À/y mice were sacrificed at age 20 weeks, and bladders were harvested, stained with H&E, and diagnosed by licensed pathologists. Uro-AR þ/y mice revealed a significantly higher incidence of BCa than did Uro-AR À/y mice (50% versus 0%). C: H&E staining for morphologic features of benign and tumorous bladder. Left panel is representative of normal bladder, and right panel is representative of BCa (circled) in a Uro-AR þ/y mouse. For statistical analysis, differences in hematuria and tumor incidence between the two groups were analyzed using Fisher's exact test. Original magnification, Â400. Scale bars: 50 mm.
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Decreased BBN-Induced Bladder Tumorigenesis in Mice Lacking Uro-AR
To detect bladder tumorigenesis at the early stage, we first used a chemical reagent dipstick to monitor hematuria, as described previously 20, 21 in the Uro-AR þ/y and Uro-AR À/y mice at age 20 weeks. There was a statistically significant difference in the detection of hematuria between Uro-AR þ/y
and Uro-AR À/y mice (65% versus 19%; P Z 0.026) ( Figure 1A ). We then examined bladder tumorigenesis in Uro-AR þ/y and Uro-AR À/y mice at age 20 weeks via histologic diagnosis and found that 50% of Uro-AR þ/y mice had noninvasive (stage pTa) urothelial carcinoma, whereas Uro-AR À/y male mice were all cancer free ( Figure 1 , B and C) (P Z 0.022). These results suggested that Uro-AR was able to promote BBN-induced bladder tumorigenesis.
AR Promotes Bladder Tumorigenesis by Facilitating Neoplastic Transformation of Normal Urothelial Cells
We further confirmed the role of Uro-AR in bladder tumorigenesis via a neoplastic transformation assay. We first established the human normal urothelial cell (SV-HUC-1) lines with stable transfection of AR (SV-HUC-AR) and vector control (SV-HUC-V). The mRNA and protein levels of SV-HUC-AR and SV-HUC-V cells were examined using real-time PCR and Western blot analysis ( Figure 2, A and B ). These stable cells were then subjected to neoplastic transformation with MCA for induction of colonies in the soft agar assay. The results showed that SV-HUC-AR cells form more colonies in soft agar than do SV-HUC-V cells ( Figure 2C ), which suggests that AR is able to promote neoplastic transformation of normal urothelial cells. Together, results from the in vivo BBN-induced bladder tumorigenesis mouse model ( Figure 1 ) and the in vitro neoplastic transformation assay ( Figure 2 ) indicated that Uro-AR was able to promote bladder tumorigenesis.
Increased p53-PCNAeMediated DNA Damage Repairing Signals in Urothelium in Mice Lacking Uro-AR
To dissect the mechanism(s) by which Uro-AR promotes BBN-induced bladder tumorigenesis, we first examined DNA damage in benign urothelium from 20-week-old Uro-AR þ/y and Uro-AR À/y mice after treatment with BBN. IHC staining with the DNA damage marker g-H2AX showed that Uro-AR þ/y mice exhibited more g-H2AX signals in the benign urothelium than did Uro-AR À/y mice ( Figure 3A) . Similar results were obtained in the urothelial cell line. SV-HUC-AR expressed a higher level of g-H2AX protein than did SV-HUC-V cells under chemical carcinogen MCA treatment ( Figure 3B ). This suggests less DNA damage under BBN or MCA challenges in the benign urothelium that lost AR, because p53, a known tumor suppressor involved in DNA repair signaling and p53 deficiency, has been linked to bladder tumorigenesis. 22 We then examined p53 expression in benign urothelium and found that urothelium from Uro-AR À/y mice expressed a significantly higher level of p53 than that from Uro-AR þ/y mice ( Figure 3C ). We also found that expression of PCNA, a key player in DNA excision repair 23 that is upregulated by p53, 24 was higher in urothelium from Uro-AR À/y mice than Uro-AR þ/y mice ( Figure 3D ). Together, data from Figure 
Uro-AR Fails to Promote Bladder Tumorigenesis in
Uro-SV40T-AR À/y Mice Lacking Active p53
To confirm that Uro-AR promotes bladder tumorigenesis through modulation of p53, we further tested the roles of Uro-AR in mice lacking active p53. We generated Uro-ARKO male mice harboring transgene UPII-SV40T (Uro-SV40T-AR À/y ) (the detailed mating strategy and confirmation are shown in Supplemental Figure S2 ), in which SV40T antigen is driven by the uroplakin II promoter. UPII-SV40T transgene mice can develop urothelial carcinoma in situ due to inactivated p53 and Rb by binding to SV40T antigen. 25 We then examined bladder tumorigenesis in both Uro-SV40T-AR þ/y and Uro-SV40T-AR À/y mice at the ages of 15, 20, and 30 weeks and found a 100% incidence of carcinoma in situ at all three ages in both genotypes of mice ( Figure 4A ). The histologic morphologic features of carcinoma in situ in Uro-SV40T-AR þ/y and Uro-SV40T-AR À/y mice were examined via H&E staining ( Figure 4B ). Furthermore, IHC staining showed little difference in p53 expression between tumors in Uro-SV40T-AR þ/y and Uro-SV40T-AR À/y mice ( Figure 4C ). These results suggest that Uro-AR is not able to promote bladder tumorigenesis in mice lacking active p53.
This conclusion was further confirmed in the in vitro neoplastic transformation assay. Adding p53 inhibitor PFT during the process of neoplastic transformation of SV-HUC-V and SV-HUC-AR cells led to little difference in colony numbers in soft agar, suggesting that loss of active p53 (via p53 inhibitor PFT) abolishes AR-promoted colony formation ( Figure 4D ).
Together, results from in vivo mouse models that lack active p53 (Figure 4 , AeC) and the in vitro neoplastic transformation assay containing p53 inhibitor ( Figure 4D ) suggest that the presence of p53 is necessary for Uro-AR to promote bladder tumorigenesis.
Uro-AR Promotes BBN-Induced BCa Development through Modulation of p53-p21
To further study the roles of Uro-AR in BCa development after tumorigenesis, we evaluated BCa development in Uro-AR þ/y and Uro-AR À/y mice at age 30 weeks. Bladder tumors (at stages pTa-pT1) were grossly identified in all Uro-AR þ/y and Uro-AR À/y mice. IHC staining showed a higher index of proliferation marker PCNA in bladder tumors developed in Uro-AR þ/y than those found in Uro-AR À/y mice ( Figure 5A ), which suggests that Uro-AR promotes cell proliferation in bladder tumors. We further detected higher expression of p21, a cell cycle modulator that controls cell proliferation and is up-regulated by p53, in BCa developed in Uro-AR À/y mice as compared with Uro-AR þ/y mice ( Figure 5B ). We also examined cell apoptosis in the tumors via TUNEL assay and found a higher apoptotic index in Uro-AR À/y mice compared with AR þ/y mice ( Figure 5C ). This cell apoptotic result is similar to that of an earlier study 26 that found that p53 expression level is positively associated with apoptosis in urothelial cells.
The results of Uro-AReregulated cell proliferation and apoptosis of bladder tumors through p53 signals were further confirmed in the tumors (carcinoma in situ) of Uro-SV40T-AR þ/y mice and Uro-SV40T-AR À/y mice at age 20 weeks. The results showed little difference in either PCNA analysis demonstrated that SV-HUC-AR stable cells expressed a higher a level of DNA damage marker g-H2AX than did SV-HUC-V stable cells after 1 and 2 hours of treatment with the carcinogen MCA. C: Uro-AR À/y urothelium expressed more p53 than did AR þ/y urothelium. p53 is well-known as a tumor suppressor involved in DNA damage repair signaling (P Z 0.007; n Z 5). D: Uro-AR À/y urothelium expressed more PCNA than did AR þ/y (P < 0.001; n Z 5). In normal cells, PCNA serves as a DNA excision repair protein that is up-regulated by p53. For statistical analysis, differences in mean values between the 2 groups were analyzed using the two-tailed t-test. Original magnification: Â400 (A, C, and D). Scale bars: 50 mm (A, C, and D).
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Increased Survival Rate in BBN-Treated Mice Lacking Uro-AR
The consequence of Uro-AR promoting BBN-induced BCa development was demonstrated by the decreased survival rate in Uro-AR þ/y mice as compared with Uro-AR À/y mice ( Figure 6 ). Considered together, our data indicate that Uro- 
Approach to Suppress BCa Development via AR Degradation Enhancer ASC-J9
Our data revealed that Uro-AR À/y mice exhibited a lower incidence of carcinogen-induced BCa than did their WT littermates, which suggests that Uro-AR promotes bladder tumorigenesis. Therefore, targeting Uro-AR using anti-AR molecules could be a potential approach to suppress BCa development. To mimic the clinical conditions of BCa, we first administered ASC-J9 in mice via daily i.p. injection of BBN-induced BCa (75 mg/kg body weight) at the first sign of hematuria and continued until the mice were aged 24 weeks. The results revealed that ASC-J9etreated mice demonstrated a significantly lower incidence of BCa than did vehicle controletreated mice (20% versus 80%) ( Figure 7A ). We also observed that ASC-J9 treatment had little effect on serum testosterone concentration (data not shown) and body weight as compared with vehicle control treatment ( Figure 7B ). These results suggested that targeting AR via ASC-J9 could be a novel approach to treat BCa at an early stage of cancer progression.
Discussion
Multiple cells are involved in the BCa microenvironment, including urothelial cells, fibroblast cells, smooth muscle cells, and infiltrating immune cells. More than 90% of bladder tumors are derived from urothelium. Finding the role of Uro-AR in promoting bladder tumorigenesis and targeting AR with ASC-J9, leading to suppression of BCa at an early developing stage, provide new insights that should help reduce BCa progression and increase survival rates. However, Uro-AR promotes bladder tumorigenesis and later progression through modulation of p53, and an early report has suggested that more than 50% of high-grade invasive BCa tumors contain dysfunctional p53. 27 Therefore, such a therapeutic approach targeting Uro-AR may yield more profound effects if administered in the stages of none muscle invasive BCa, which contains more functional p53 expression. Furthermore, as early studies have suggested that recurrence of BCa might be associated with expression of Uro-AR, 12 it will be beneficial if additional clinical studies prove targeting Uro-AR via ASC-J9 leads to suppression of BCa recurrence.
Our results suggest that the dominance of Uro-AR in BCa is due to modulation of p53 activity. Loss of p53 function has been associated with bladder tumorigenesis and BCa progression. For bladder tumorigenesis, Ozaki et al 28 have reported that p53-positive and p53-negative knockout mice have a higher incidence of BBN-induced BCa than do WT mice. In addition, Gao et al 22 have suggested that p53 deficiency synergizes with activated Ha-ras in promoting bladder tumorigenesis. For BCa progression, both grade and BCa. At age 6 weeks, male Uro-AR þ/y mice (n Z 22) and Uro-AR À/y mice (n Z 11) were initially given drinking water containing BBN for 12 weeks. Mice survival data were recorded weekly. The urinary tract organs (kidney, ureters, bladder, and urethra) from deceased mice were harvested for diagnosis of cause of death. The results showed that male Uro-AR À/y mice had higher survival rates than did male AR þ/y mice (100% versus 50%). The difference in survival rate was analyzed using the log-rank (Mantel-Cox) test. Body Weight (g) Figure 7 Suppression of bladder tumorigenesis by the AR degradation enhancer ASC-J9. A: Reduced bladder tumorigenesis in male mice using ASC-J9 via i.p. injection. Twenty FVB male mice were subjected to BBN treatment for 12 weeks to induce BCa. As soon as the first mouse was found to have hematuria (<50 erythrocytes/mL blood), all mice were subjected to daily i.p. injection of vehicle or ASC-J9 (75 mg/kg body weight; n Z 10).
The results showed that mice given ASC-J9 had a significantly lower incidence of BCa than did mice given vehicle (20% versus 80%; P Z 0.023). Difference in tumor incidence between the two groups was analyzed using Fisher's exact test. B: ASC-J9 had no effect on body weight of mice after 8 weeks of treatment. Body weight was measured at ages 16 and 24 weeks. There was no difference in body weight between the control and ASC-J9 groups at age 16 or 24 weeks. The difference in mean body weight between the two groups was analyzed using the two-tailed Student's t-test.
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The mechanism by which Uro-AR negatively regulates p53 activity was not examined in our study. However, earlier reports provide two mechanisms that may support our conclusion. Nantermet et al 31 indicated that p53 activity is negatively regulated by AR activation without changing p53 RNA level. Experiments from prostate cancer (PCa) LNCaP cells indicate that AR suppresses accumulation of p53 in the nucleus, which suggests that AR may negatively regulate p53 activity through a posttranscriptional mechanism. Beitel et al 32 indicated that the AR N-terminal transactivaton domain can interact with PIRH2 (p53-induced RING-H2 protein), a p53-induced ubiquitin-protein, which promotes p53 degradation. 33 Lin et al 34 also indicated that suppressing AR via siRNA induces p53 protein expression through PIRH2 and further promotes downstream p21 expression and results in increased apoptosis, which provides the other mechanism in which AR suppresses p53 activity through ubiquitin-induced protein degradation.
CD24, a glycosyl phosphatidylinositol-linked sialoglycoprotein, has been associated with urothelial carcinoma and contributes to BCa progression. 35, 36 That the mechanism by which CD24 mediates BCa development may be through androgen/AR signaling was further suggested by Overdevest et al, 37 who used the BBN-induced cancer model with CD24-deficient male mice to demonstrate that such mice have a lower incidence of bladder tumor and delayed bladder malignancy, including metastasis and death. In the molecular mechanical dissection, they found that CD24 mRNA and protein expression are androgen dependent and that AR activation can induce CD24 promoter activity in human BCa cell lines. The in vivo results of Overdevest et al 37 are consistent with our finding in Uro-ARKO mice, both of which suggested that AR is involved in bladder tumorigenesis, cancer progression, and mortality. This conclusion provides a solid rationale for BCa treatment that targets AR.
Uro-AR had positive roles in promoting both bladder tumorigenesis and tumor progression, which was in apposition to early findings that showed dual yet opposing roles of AR in PCa 38, 39 and hepatocellular carcinoma. 40 In PCa, AR functions as a proliferator in PCa stroma cells, a survivor in PCa luminal epithelial cells, and a suppressor in PCa basal epithelial cells. 38, 39 In hepatocellular carcinoma, AR was found to promote tumorigenesis, 40 yet functioned as a suppressor for hepatocellular carcinoma metastasis, 41 which could be due to different intracellular signals in the same hepatocytes at various stages. 41 In the present study, we found that Uro-AR had a consistent role in promoting BCa progression at tumorigenesis and tumor progression, which could be due to suppression of p53 expression or function.
In a previous study, 12 we showed that the urothelium of general ARKO mice implanted with dihydrotestosterone pellets has significantly higher apoptotic signals than does that of WT mice after BBN treatment. This result provides evidence that lacking AR in the urothelium can promote BBN-induced cell apoptosis ( Figure 5C ). It has been reported that p53 activity is negatively regulated by AR activation 31 and that p53 can induce BAX activation, which promotes cell apoptosis. 42 Therefore, we speculate that the possible mechanism behind the data in Figure 5C is that lost or decreasing AR expression in urothelium induces p53 activation, which promotes urothelial apoptosis through p53 downstream target genes such as Bax. An earlier study also suggested that apoptosis may be closely associated with carcinogenesis and tumor invasion of the rat bladder induced by BBN, 43 which supports the data in Figure 5C . Umbrella cells are the first lining layer of urothelial cells, which directly contacts with urine in the bladder lumen. Therefore, umbrella cells have a higher risk of being exposed to urinary carcinogens. Indeed, urinary carcinogens are associated with the risk of BCa. 44e47 In the present study, the major urinary metabolite of BBN was BCPN. 48 After a-hydroxylation, BCPN chemically induced DNA alkylation on urothelial cells 49 and resulted in phosphorylation of H2AX. 50 Therefore, our data ( Figure 3 ) suggest that g-H2AX signals shown in umbrella cells may be due to direct exposure to BCPN in the urine. Furthermore, not all bladder tumors derive from basal cells. Cytokeratin 20, an umbrella cell marker, has been reliably observed in the primary tumor and its matched lymph node metastasis. 51 p63 is a member of the p53 family, which encodes multiple products with transactivating, death-inducing, and dominant-negative activities, 52 and Guo et al 53 have suggested that p63 could induce senescence and suppress tumorigenesis in vivo. Moreover, a clinical report has also indicated that altered expression of p63 is associated with Benign Urothelium Urothelial Carcinoma Figure 8 Mechanisms by which Uro-AR regulates bladder tumorigenesis and BCa development. In benign bladder tissues, Uro-AR promotes the carcinogen-induced DNA damage signal (g-H2AX) by suppressing p53 and its downstream PCNA expression, which contributes to DNA damage repair. This accumulated DNA damage is thought to contribute to later tumorigenesis. After bladder tissues become malignant, Uro-AR also promotes tumor growth by suppressing p53, thereby preventing downstream activation of p21, which normally induces cell cycle arrest. Suppression of p53 also inhibits cell apoptosis. Uro-AR promotes tumor growth and causes death of the animal due to obstruction of the urinary tract.
human BCa. 54 We have used IHC staining to examine the p63 protein expression on the normal urothelium of wild-type and Uro-ARKO mice at age 20 weeks after BBN treatment. The results showed that p63 protein expression level is significantly higher in Uro-ARKO mouse urothelium than in WT mouse urothelium (Supplemental Figure S3) , whereas Uro-ARKO mice have a lower rate of bladder cancer than do WT mice ( Figure 1B) . Therefore, our results suggest that elevated p63 expression in Uro-ARKO urothelium is associated with a lower incidence of BCa. This conclusion is consistent with the references described previously.
In summary, using multiple in vitro and in vivo approaches, our results demonstrate that Uro-AR consistently promotes bladder tumorigenesis, tumor progression, and animal death. We further dissected the mechanisms by which Uro-AR regulates BCa development through p53 (Figure 8 ). The present study revealed that AR degradation enhancer ASC-J9 could substantially suppress bladder tumorigenesis in a carcinogen-induced BCa mouse model, which suggests that Uro-AR is a potential target against BCa.
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